VI.e

Fat/oil embolism

Migration of exogenous oil or lipids or endogenous fat into the distal pulmonary microcirculation can cause a syndrome of acute coughing, hypoxemia, pulmonary hypertension, pulmonary infiltrates and/or ARDS. Neurologic or visual impairment and obtundation characterizes those cases with transpulmonary shunting of oil/fat and have a guarded prognosis. Silicone embolism (see under VIm) is a closely-related syndrome. Iodinated oil embolism, a nearly specific complication of TACE is electron-dense on imaging (better visualized on non-enhanced CT). Imaging features: PMID 23102488

Last update : 06/11/2017
 

Causative drugs

22

Corticosteroids, systemic (oral, parenteral)

I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism
VI.ad VI - Pulmonary vasculopathy
VI.ad - Right ventricular outflow tract compression
VII.c VII - Mediastinal involvement
VII.c - Mediastinal lipomatosis
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VII.j VII - Mediastinal involvement
VII.j - Compression of mediastinal structures/organs
VIII.g VIII - Upper, central, large airway involvement
VIII.g - Tracheal narrowing - Sabre sheath trachea
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup
IX.m IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.m - Epidural thoracic lipomatosis
IX.v IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.v - Myopathy/muscle weakness or paralysis
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.n X - Systemic conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.as X - Systemic conditions, syndromes and reactions
X.as - Scleroderma renal crisis
X.av X - Systemic conditions, syndromes and reactions
X.av - Hypogammaglobulinemia-Antibody deficiency (see under XVIIw)
XI.v XI - Miscellaneous
XI.v - Rib fracture
XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture
XI.ai XI - Miscellaneous
XI.ai - Cushing syndrome
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.v XII - Cardiovascular involvement / toxicity
XII.v - Hypertrophic cardiomyopathy
XVI.at XVI - Imaging
XVI.at - Imaging: Subpleural fat deposits
XVI.au XVI - Imaging
XVI.au - Imaging: Mediastinal fatty deposits
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.o XVII - Infections & related conditions
XVII.o - Nocardia pulmonary infection
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.v XVII - Infections & related conditions
XVII.v - Strongyloides stercoralis hyperinfection (w/wo DAH)
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
XVII.ai XVII - Infections & related conditions
XVII.ai - A falsely negative/indeterminate IGRA test result
1

Excipients - Vehicle - Preservatives

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis, talcosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.i IV - Airway involvement
IV.i - Foreign body aspiration bronchiolitis
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism
VI.g VI - Pulmonary vasculopathy
VI.g - Foreign body vasculopathy (Excipient lung disease)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XV.ae XV - Pulmonary pathology
XV.ae - Path: Lipid/fat embolism (see also VIe)
XVI.q XVI - Imaging
XVI.q - Imaging: A pattern similar/consistent to/with IPF
XVI.v XVI - Imaging
XVI.v - Imaging: Diffuse centrilobular micronodules
1

Propofol

II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.f II - Pulmonary edema - ARDS - Acute respiratory failure
II.f - Hypoxemia, low saturation (may occur in isolation)
II.i II - Pulmonary edema - ARDS - Acute respiratory failure
II.i - Flash (fulminate) pulmonary edema
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.b IV - Airway involvement
IV.b - Bronchospasm and angioedema
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.e IV - Airway involvement
IV.e - Cough (acute, violent, explosive)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism
VIII.h VIII - Upper, central, large airway involvement
VIII.h - Vocal cord dysfunction, adduction, closure
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
IX.p IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.p - Disordered breathing during sleep
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.aa X - Systemic conditions, syndromes and reactions
X.aa - Propofol infusion syndrome (PRIS)
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XI.x XI - Miscellaneous
XI.x - Addictive risk
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole
XV.ae XV - Pulmonary pathology
XV.ae - Path: Lipid/fat embolism (see also VIe)
1